ImpediMed receives FDA clearance

Company News

by Jessica Ellerm

ImpediMed Limited (ASX:IPD) has announced the US FDA has issued it with market clearance for its SOZOTM product.

SOZOTM is a connected platform that monitors fluid levels in heart failure patients, and is used under the direction of a physician in the clinic or home environments.

The clearance is another important regulatory milestone for the business, as it looks to provide a new model of care for cancer and heart failure patients.

Studies involving the use of SOZOTM technology have demonstrated detectable differences in whole-body extra-cellular fluid as low as 0.1 litres.

ImpediMed Limited (ASX:IPD) was trading around 5.91% higher this morning at $0.98

Jessica Ellerm

Finance News Network
Jessica joined FNN in April 2016 and presents the Australian Share Market Outlook, and reports on the morning's leading business stories. Alongside FNN Jessica is a fintech industry commentator, writing for her own blog and a number of international online publications.